• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Latest News about treatment/resistant depression

    Recent news which mentions treatment/resistant depression

    Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant
    Tickers ATAI
    Tags Benzinga ATAI Life Sciences Market News
    From Benzinga
    Pharma Giant Johnson & Johnson Asks FDA To Approve Esketamine Nasal Spray For Treatment-Resistant Depression
    Tickers JNJ NEWS
    Tags Psychedeclis for TDR eketamine nasal spray Cannabis
    From Benzinga
    First Patient Dosed In Psychedelics Therapy Study For Treatment-Resistant Depression
    Tickers NEWS
    Tags Beckley Psytech Ltd Beckley Psytech Cannabis
    From Benzinga
    Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression
    Tickers ATAI NEWS
    Tags 5/MeO/DMT Psychedelics Research treatment/resistant depression
    From Benzinga
    Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment
    Tickers CMPS
    Tags treatment/resistant depression Management Psychedelic/Assisted Therapies
    From Benzinga
    UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center
    Tickers AWKNF CMPS
    Tags Psilocybin program News treatment/resistant depression
    From Benzinga
    Atai Life Sciences Completes Phase 1 Clinical Study Of Oral Film DMT Formulation
    Tickers ATAI
    Tags Management treatment/resistant depression News
    From Benzinga
    Compass Pathways Explores AI-Powered Predictive Model On Psilocybin Therapy For Depression
    Tickers CMPS
    Tags Management treatment/resistant depression Rumors
    From Benzinga
    GH Research Psychedelics Firm Q2 2023 Reports $238M Cash To Accelerate 5-MeO-DMT Programs Into 2026
    Tickers GHRS
    Tags Psychedelic/Assisted Therapies GHRS 5/MeO/DMT
    From Benzinga
    Compatibility Of Psilocybin & SSRIs For Depression, COMPASS Looks At 'Psychedelic-Assisted Therapies'
    Tickers CMPS
    Tags FDA CMPS Psychedelic/Assisted Therapies
    From Benzinga
    COMPASS Pathways Secures Up To $50M In Term Loan Facility With Hercules Capital
    Tickers ATAI CMPS HTGC
    Tags Management treatment/resistant depression News
    From Benzinga
    Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD
    Tickers CMPS NUMIF
    Tags treatment/resistant depression News Psilocybin program
    From Benzinga
    GH Research: Q1 2023 Financials And Businesses For European 5-MeO-DMT Depression Treatment Developer
    Tickers GHRS
    Tags Markets Guidance Cannabis
    From Benzinga
    Beckley Psytech Begins Phase IIa Study Of Psychedelic Compound To Treat Depression
    Tags Cannabis Markets Dr/ Rob Conley
    From Benzinga
    Cathie Wood Reacts To Atai's Drastic Stock Plunge After Doomed Clinical Study Results
    Tickers ATAI CMPS IGXT
    Tags atai Cannabis ATAI
    From Benzinga
    Magic Mushrooms Tested For Treating Type II Bipolar Disorder, Check Out Results So Far
    Tickers CMPS
    Tags bipolar disorder Psychedelics Market News
    From Benzinga
    Psychedelics And Treatment-Resistant Depression: COMPASS Pathways Replies To Comments
    Tickers CMPS
    Tags Benzinga Psychedelics Market News
    From Benzinga
    Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS' Latest Trial Outcomes
    Tickers CMPS
    Tags Benzinga Market News Psychedelics
    From Benzinga
    Psychedelics Company's $60M Series A For Startup To Develop Treatment For Mental Health Disorders
    Tags Contracts treatment/resistant depression News
    From Benzinga
    atai's Phase 1 Synthetic DMT-Based Drug Clinical Trial Begins Patient Dosing
    Tickers ATAI
    Tags DMT Clinical Trial Penny Stocks treatment/resistant depression
    From Benzinga
    Psilocybin For Anorexia: Learn About Compass' Novel Phase 2 Trial Using Magic Mushroom's Main Compound
    Tickers CMPS
    Tags Columbia University Irving Medical School Psychedelics Market News
    From Benzinga
    Psilocybin More Effective Than Antidepressants In Treating Depression, New Study Shows
    Tags Benzinga Psychedelics Market News
    From Benzinga
    COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction
    Tickers CMPS
    Tags Markets CMPS Compass Pathways
    From Benzinga
    Mike Tyson: How A Drug Derived From Toad Venom Made Him Comfortable With Dying
    Tickers GHRS
    Tags GHRS toad venom Success Stories
    From Benzinga
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.